Home About
Back to Search

Fosaprepitant

FOSAPREPITANT

Manufacturer: Dr. Reddy's Laboratories Inc.,

Score: 141.0

Quick Summary

Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC). The recommended dosage is 150 mg administered as an intravenous infusion over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy. Fosaprepitant is contraindicated in patients with hypersensitivity to any component of the product and in patients taking pimozide. The most common adverse reactions include fatigue, diarrhea, neutropenia, asthenia, anemia, and peripheral neuropathy.

Key Clinical Findings and Indications

  • Prevention of acute and delayed nausea and vomiting associated with HEC
  • Prevention of acute and delayed nausea and vomiting associated with MEC

Important Safety Information

Warning

Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported

Contraindications

  • Hypersensitivity to any component of the product
  • Concurrent use with pimozide

Adverse Reactions

  • Fatigue
  • Diarrhea
  • Neutropenia
  • Asthenia
  • Anemia
  • Peripheral neuropathy

Dosing Recommendations

HEC

Adult Dose

150 mg intravenously over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy

Pediatric Dose

MEC

Adult Dose

150 mg intravenously over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy

Pediatric Dose

Special Population Considerations

Pregnancy

  • There are insufficient data on use of fosaprepitant in pregnant women to inform a drug-associated risk

Nursing Mothers

  • The efficacy of hormonal contraceptives may be reduced during treatment with fosaprepitant

Pediatric Use

  • The safety and effectiveness of fosaprepitant have not been established in patients less than 6 months of age

Geriatric Use

  • Use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy

Similar Drugs

Fosaprepitant

FOSAPREPITANT DIMEGLUMINE

BluePoint Laboratories

Similarity: 94.5%

Fruzaqla

FRUQUINTINIB

Takeda Pharmaceuticals America, Inc.

Similarity: 61.1%

AKYNZEO

NETUPITANT AND PALONOSETRON

Helsinn Therapeutics (U.S.), Inc.

Similarity: 60.7%

TUKYSA

TUCATINIB

SEAGEN INC.

Similarity: 60.4%
Back to Search